BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

...Asahi Kasei Pharma ATS907 Ophthalmic disease Glaucoma Phase II Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) Y-39983...
BioCentury | May 21, 2012
Emerging Company Profile

Amakem: Switching off side effects

...>=120 minutes vs. the vehicle-treated control eye (p<0.05). AMA0076 also led to lower hyperemia vs. Y-39983...
BioCentury | May 14, 2012
Clinical News

Amakem preclinical data

...minutes vs. the vehicle-treated control eye (p<0.05). Additionally AMA0076 led to lower ocular hyperemia vs. Y-39983...
Items per page:
1 - 3 of 3